Glenmark Pharmaceuticals Balance Sheet Annual
BSE: - | NSE: - | ISIN: - | Sector: -2,276.10 +10.85 (0.48%)Updated : 10 Jul 2026
| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Liabilities Shareholders' Equity | 19,907.88 | 16,049.55 | 14,358.62 | 19,371.68 |
| Other Liabilities Total | 2,532.12 | 475.96 | 540.52 | 956.40 |
| Long Term Debt | 0.00 | 512.70 | 0.00 | 3,852.14 |
| Common Stock Total | 28.22 | 28.22 | 28.22 | 28.22 |
| Other Current Assets Total | 1,506.14 | 52.25 | 23.26 | 41.98 |
| Total Assets | 19,907.88 | 16,049.55 | 14,358.62 | 19,371.68 |
| Current Portof LT Debt/ Capital Leases | 107.22 | 92.26 | 245.88 | 228.62 |
| Cash | 1,174.71 | 1,675.71 | 1,658.27 | 1,159.20 |
| Total Equity | 10,512.11 | 8,849.44 | 7,847.93 | 9,473.92 |
| Long Term Investments | 109.88 | 56.36 | 789.66 | 44.57 |
| Retained Earnings( Accumulated Deficit) | 10,483.89 | 8,990.15 | 8,060.97 | 9,640.27 |
| Total Common Shares Outstanding | 28.22 | 28.22 | 28.22 | 28.22 |
| Tangible Book Valueper Share Common Eq | 283.70 | 261.85 | 230.82 | 250.12 |
| Goodwill Net | 82.86 | 70.27 | 67.36 | 73.62 |
| Total Liabilities | 9,395.77 | 7,200.11 | 6,510.70 | 9,897.75 |
| Total Debt | 593.53 | 2,472.67 | 1,230.93 | 4,607.88 |
| Short Term Investments | 224.73 | - | - | - |
| Cashand Short Term Investments | 1,399.44 | 1,675.71 | 1,658.27 | 1,159.20 |
| Total Receivables Net | 4,963.35 | 4,181.06 | 2,999.01 | 4,488.42 |
| Notes Payable/ Short Term Debt | 0.00 | 1,681.50 | 833.36 | 350.00 |
| Deferred Income Tax | 1.23 | 58.59 | 0.28 | 0.51 |
| Accounts Receivable- Trade Net | 4,963.35 | 3,341.95 | 1,858.41 | 3,665.17 |
| Property/ Plant/ Equipment Total- Net | 4,317.44 | 3,861.35 | 3,537.48 | 4,195.10 |
| Minority Interest | -0.32 | -0.37 | -0.38 | 365.34 |
| Total Current Liabilities | 6,376.43 | 5,967.02 | 5,818.59 | 4,546.24 |
| Total Inventory | 3,430.78 | 3,281.20 | 2,720.85 | 2,506.54 |
| Accounts Payable | 3,743.87 | 2,595.69 | 2,607.73 | 2,042.15 |
| Other Currentliabilities Total | 2,525.33 | 673.32 | 1,041.00 | 642.02 |
| Total Long Term Debt | 486.31 | 698.91 | 151.69 | 4,029.26 |
| Intangibles Net | 2,423.36 | 1,390.03 | 1,267.21 | 2,342.68 |
| Other Long Term Assets Total | 1,443.48 | 1,202.14 | 1,120.88 | 4,140.24 |
| Note Receivable- Long Term | 231.13 | 173.94 | 147.95 | 151.83 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 11,299.71 | 9,295.47 | 7,428.08 | 8,423.64 |
| Capital Lease Obligations | 486.31 | 186.21 | 151.69 | 177.12 |
| Accumulated Depreciation Total | - | -2,793.48 | -2,492.40 | -2,264.15 |
| Accrued Expenses | - | 924.25 | 1,090.62 | 1,283.46 |
| Other Equity Total | - | -1,855.49 | -1,927.82 | -1,879.92 |
| Prepaid Expenses | - | 105.25 | 26.69 | 227.50 |
| Additional Paid- In Capital | - | 1,686.56 | 1,686.56 | 1,685.36 |
| Property/ Plant/ Equipment Total- Gross | - | 6,112.84 | 5,610.55 | 5,393.42 |
*All figures in crores except per share values
Glenmark Pharmaceuticals Quick Links
Glenmark Pharmaceuticals Dividend Glenmark Pharmaceuticals Bonus Glenmark Pharmaceuticals News Glenmark Pharmaceuticals AGM Glenmark Pharmaceuticals Rights Glenmark Pharmaceuticals Splits Glenmark Pharmaceuticals Board Meetings Glenmark Pharmaceuticals Key Metrics Glenmark Pharmaceuticals Shareholdings Glenmark Pharmaceuticals Profit Loss Glenmark Pharmaceuticals Cashflow Glenmark Pharmaceuticals Q1 Results Glenmark Pharmaceuticals Q2 Results Glenmark Pharmaceuticals Q3 Results Glenmark Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
1,845.00+45.70(2.54%)
1,456.05+31.80(2.23%)
1,072.00+21.95(2.09%)
289.70-2.55 (-0.87%)
1,916.05-14.45 (-0.75%)
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.